Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Image of Young T.Kwon and the Alchemab Therapeutics logo

Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of Young T. Kwon, PhD as Chief Financial and Operating Officer.

Dr Kwon brings over 20 years of experience in the biopharma and venture capital sectors. Most recently, he served as Chief Financial and Business Officer of Momenta Pharmaceuticals, where he was responsible for business development, strategy, finance, investor relations, and commercial. In that role, he led equity financings raising nearly $500 million and led the company’s sale to Johnson & Johnson for $6.5 billion.

Before Momenta, Dr Kwon was a business development professional at Biogen, driving a variety of transactions. Dr Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies.

Dr Kwon is a member of the board of directors of ADMA Biologics, a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing speciality plasma-derived biologics. He is also a scientific advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies.

Dr Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.


We are thrilled to welcome Young to the Alchemab management team and look forward to drawing from his extensive experience as a biotech leader over the last two decades. His outstanding track record in value creation will play a key role as we continue our platform expansion into new areas and move our lead programs towards the clinic. - Douglas A. Treco, PhD, Chief Executive Officer of Alchemab Therapeutics


I am excited to join Alchemab, a company with a truly unique platform that can generate multiple product candidates derived from patients resilient to disease. While the company is initially focused on oncology and neurodegenerative diseases, the potential to identify novel therapeutics across the full range of unmet needs is almost unlimited. I am eager to work alongside this talented team to support the company’s financial and corporate development objectives and to build a robust pipeline based on our innovative approach of discovering convergent protective antibodies.
- Dr Kwon, CFO and COO at Alchemab Therapeutics


Young’s ability to build talented teams around transformative science is a great fit for Alchemab and we are delighted that he will be joining us at a time when we are really starting to build our understanding of how the human immune system is driving resilience to disease.
- Jane Osbourn, Co-founder and CSO at Alchemab Therapeutics

Click here to see the original article